Oral Weight Loss Pill Orforglipron Helps Maintain Results After Injectable GLP-1 Drugs

Two new randomized studies published in Nature Medicine demonstrate that daily oral orforglipron helps patients maintain most of the weight loss achieved with injectable GLP-1 drugs such as tirzepatide and semaglutide. The double-blind, placebo-controlled trial enrolled 376 adults across 29 sites in the United States who had completed 72 weeks of treatment in the SURMOUNT-5 study.

Participants were randomized to receive orforglipron at a maximum tolerated dose of 36 mg or placebo once daily for 52 weeks. Among those who had reached a weight plateau on tirzepatide, orforglipron users maintained 74.7 percent of their prior weight reduction after one year compared with 49.2 percent for the placebo group.

The estimated treatment difference was 25.5 percentage points. Patients previously treated with semaglutide who switched to orforglipron retained 79.3 percent of their weight loss versus 37.6 percent on placebo, producing an estimated treatment difference of 41.7 percentage points.

Both primary endpoints reached statistical significance with P values below 0.001. All key secondary endpoints were also met. More than half of semaglutide patients on orforglipron maintained at least 80 percent of their prior weight loss, compared with fewer than 7 percent on placebo.

Participants who continued orforglipron also preserved improvements in waist circumference, blood pressure, lipids, fasting glucose and HbA1c levels achieved during the injectable phase. At the end of the maintenance year, mean body weight stood at approximately 96 kg for the tirzepatide-to-orforglipron cohort.

The medication, a nonpeptide GLP-1 receptor agonist taken without food or water restrictions, received FDA approval last month. It remains unlicensed in Britain. Gastrointestinal effects were the most common adverse events and were mostly mild to moderate.

The trial did not include a comparator arm of patients who continued injectable therapy.

Marie Spreckley, research programme manager at the University of Cambridge, said one of the most valuable aspects of this study is that it reflects a highly realistic clinical scenario. She noted many people do not want to remain on injectable therapy indefinitely due to treatment burden, convenience, travel, storage requirements, cost or personal preference.

Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said injectable medications carry substantial costs that limit their long-term applicability for both private purchasers and the NHS. He added that oral alternatives are considerably less expensive to produce.

The studies noted that weight regain typically occurs after stopping injectable GLP-1 drugs. Orforglipron offers a potential option for minimizing such regain while addressing barriers associated with injections. Trial limitations include its one-year duration and the absence of a continued-injectable comparator arm.

Larger studies will be needed to confirm long-term outcomes. " — Nature Medicine study authors, 2026 (Nature Medicine) The findings arrive as demand for obesity treatments grows and health systems seek sustainable approaches to long-term weight management.